Rapid Micro Biosystems Reports Q1 Results with Strong Revenue Growth, High Cash Burn, Reaffirms 2026 Guidance

summarizeSummary

Rapid Micro Biosystems announced Q1 2026 results showing revenue growth and reaffirmed 2026 guidance, but reported a substantial increase in net loss and a significant reduction in cash, raising critical liquidity concerns.

check_boxKey Events

• Q1 2026 Revenue Growth

  Total revenue increased 11.1% year-over-year to $8.0 million, with product revenue up 36% and recurring revenue up 28%.

• Increased Net Loss

  Net loss widened to $14.3 million ($0.31 per share) in Q1 2026, compared to $11.3 million ($0.26 per share) in Q1 2025.

• Significant Cash Burn

  Cash, cash equivalents, and short-term investments decreased by $15.35 million, from $38.6 million at year-end 2025 to $23 million as of March 31, 2026, indicating a rapid depletion of liquidity.

• 2026 Guidance Reaffirmed

  The company reaffirmed its full-year 2026 revenue guidance of $37.0 million to $41.0 million and gross margin guidance of approximately 20%.

auto_awesomeAnalysis

Rapid Micro Biosystems reported strong Q1 2026 revenue growth, driven by increased product sales and recurring revenue, and reaffirmed its full-year 2026 guidance. However, the company experienced a significant cash burn, with cash and equivalents dropping from $38.6 million to $23 million in one quarter. This rapid depletion of liquidity raises serious concerns about the company's cash runway, especially in light of the previously stated 12-month liquidity runway from the March 12, 2026 10-K filing. The net loss also widened.